Deutsche Bank
http://www.db.com/
Deutsche Bank is a leading global investment bank with a strong and profitable private clients franchise.
The company operates through three divisions: Corporate and Investment Bank (CIB), Private Clients and Asset Management (PCAM) and Corporate Investments (CI) . The CIB division engages in the origination, sale, financing, structuring, and trading of fixed income, equity, equity-linked, convertible bond, foreign exchange, and commodities products. The PCAM segment provides portfolio/fund management products, including active fund management, passive/quantitative fund management, alternative investments, and discretionary portfolio management solutions in Germany and other continental European countries.-
-
-
-
-
-
-
Biogen (BIIB) PT Lowered to $371 at Deutsche Bank
-
-
-
-
-
-
-
Deutsche Bank Starts Biogen (BIIB) at Buy; Focus on Earnings Power and Execution
-
-
-
-
-
-
-
Deutsche Bank Continues to See 25% Probability of Biogen (BIIB) Success in Alzheimer's
-
-
-
-
-
-
-
Notable 52-Week Highs and Lows 3/20: (FB) (BIIB) (NKE) High; (YOKU) (VNCE) (RENN) Low
-
-
-
-
-
-
-
Baxter (BAX) Break-Up Resembles Abbott/Abbvie - Deutsche Bank
-
-
-
-
-
-
-
Biogen (BIIB) SMNrx Looks Ok at High Dose - Deutsche Bank
-
-
-
-
-
-
-
5 Reasons to Own Biogen (BIIB) - Deutsche Bank
-
55,950 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

